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Abstract
We describe, for the first time, hydrogel-forming microneedle arrays prepared from ‘‘super swelling’’ polymeric
compositions. We produced a microneedle formulation with enhanced swelling capabilities from aqueous blends
containing 20% w/w Gantrez S-97, 7.5% w/w PEG 10,000 and 3% w/w Na2CO3 and utilised a drug reservoir of a lyophilised
wafer-like design. These microneedle-lyophilised wafer compositions were robust and effectively penetrated skin, swelling
extensively, but being removed intact. In in vitro delivery experiments across excised neonatal porcine skin, approximately
44 mg of the model high dose small molecule drug ibuprofen sodium was delivered in 24 h, equating to 37% of the loading
in the lyophilised reservoir. The super swelling microneedles delivered approximately 1.24 mg of the model protein
ovalbumin over 24 h, equivalent to a delivery efficiency of approximately 49%. The integrated microneedle-lyophilised
wafer delivery system produced a progressive increase in plasma concentrations of ibuprofen sodium in rats over 6 h, with a
maximal concentration of approximately 179 mg/ml achieved in this time. The plasma concentration had fallen to
7166.7 mg/ml by 24 h. Ovalbumin levels peaked in rat plasma after only 1 hour at 42.36617.01 ng/ml. Ovalbumin plasma
levels then remained almost constant up to 6 h, dropping somewhat at 24 h, when 23.6164.84 ng/ml was detected. This
work represents a significant advancement on conventional microneedle systems, which are presently only suitable for
bolus delivery of very potent drugs and vaccines. Once fully developed, such technology may greatly expand the range of
drugs that can be delivered transdermally, to the benefit of patients and industry. Accordingly, we are currently progressing
towards clinical evaluations with a range of candidate molecules.
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Introduction
Microneedle (MN) arrays, micron scale, minimally-invasive
devices that painlessly by-pass the skin’s stratum corneum barrier,
have been shown to be extremely effective in enhancing
transdermal delivery of water soluble drugs, biomolecular thera-
peutics and vaccines [1–3]. The compounds delivered to date have
typically been of high potency, meaning only a low dose is
required to achieve a therapeutic affect (e.g. insulin) [4,5] or elicit
the required immune response [6,7]. Clearly, the majority of
marketed drug substances, including many antibodies, are not low
dose, high potency molecules. Indeed, many drugs require doses of
several hundred milligrams per day in order to achieve therapeutic
plasma concentrations in man. Until now, such high doses could
not be delivered transdermally from a patch of reasonable size,
even for molecules whose physicochemical properties are ideal for
passive diffusion across the skin’s stratum corneum barrier.
Therefore, transdermal delivery has traditionally been limited to
fairly lipophilic, low molecular weight, high potency drug
substances. Since most drugs do not possess these properties, the
transdermal delivery market has not expanded beyond around 20
drugs. Marketed MN-based patches are likely to increase this
number of drugs in the coming years. However, this increase will
only be maximised if high dose molecules can be delivered in
therapeutic doses using MN. We have previously shown that
suitably-formulated dissolving MN platforms can deliver thera-
peutic doses of a low potency, high dose drug substance [8].
However, deposition of polymer in skin from a dissolving MN
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system may be undesirable if the system is to be used on an
ongoing basis. The dissolving MN system employed in this
previous study would deposit approximately 5–10 mg of polymer
per cm2 in skin [8]. If the patch size were 10 cm2, then 50–100 mg
of polymer would be deposited in the patient’s skin every time the
product is applied. While vaccines are used infrequently, most
therapeutic agents need to be administered regularly. Accordingly,
dissolving MN systems may be most appropriate to rapid delivery
of low dose vaccines [6,9].
We have recently described novel hydrogel-forming MN arrays,
prepared under ambient conditions that contain no drug
themselves [10]. Instead, they rapidly imbibe skin interstitial fluid
upon insertion to form continuous, unblockable conduits between
the dermal microcirculation and an attached patch-type drug
reservoir. Such hydrogel-forming MN initially act simply as a tool
to pierce the stratum corneum barrier. Upon insertion, they
function as a rate-controlling membrane, allowing sustained drug
delivery at a rate controllable by adjustment of crosslink density,
which dictates swelling rate [10,11]. Importantly, such MN are
removed intact from skin, leaving no measurable polymer residue
behind, but are sufficiently softened, even after 1 minute of skin
insertion to preclude reinsertion, thus further reducing the risk of
transmission of infection [12]. In the present study, we substan-
tially modified this novel system to facilitate delivery of clinically-
relevant doses of a low potency, high dose drug substance and
rapid delivery of a model protein by using a modifying agent to
increase swelling capabilities [13] and using a hygroscopic
lyophilised drug reservoir (Figure 1).
Methods and Materials
2.1. Chemicals
Polyethylene glycol (PEG, MW 10,000 Da), ibuprofen-sodium,
chicken ovalbumin (OVA, albumin from chicken egg, grade IIV),
mouse monoclonal anti-chicken ovalbumin antibody (moAb), Ph.
Eur. Gelatin, D-mannitol and tetramethylbenzidine (TMB)
substrate were purchased from Sigma-Aldrich, Dorset, UK.
Phosphate buffered saline tablets, pH 7.4 (PBS) were obtained
from Oxoid Ltd., Hampshire, UK. Rabbit anti-ovalbumin horse-
radish peroxidase (HRP) conjugated-polyclonal antibody was
purchased from Gene Tex Inc Alton Pkwy, Irvine, USA.
SuperBlock T20 was purchased from Thermo Scientific, Rock-
ford, Illinois, USA. 50C-Mannitol was supplied by Roquette,
Lestrem, France. Gantrez AN-139 and S-97, copolymers of
methyl vinyl ether and maleic anhydride and methyl vinyl ether
and maleic acid, respectively (PMVE/MAH and PMVE/MA,
with molecular masses of 1,080,000 and 1,500,000 respectively)
were gifts from Ashland, Kidderminster, UK. Unless otherwise
stated, all other chemicals and materials were supplied by Sigma-
Aldrich (Dorset, UK) or Fisher Scientific (Loughborough, UK).
2.2. Preparation of hydrogel films
The aim here was to investigate various polymeric compositions
in order to find a material capable of rapid swelling, but which
would be sufficiently hard in the dry state to penetrate the skin.
Importantly, once swollen, the material should maintain structural
integrity and be reasonably robust during handling.
Stock solutions of Gantrez S-97 (40% w/w) or AN-139 (30% w/
w) [13,14] were prepared using deionised water (Figure 2A).
Hydrogel films were then prepared using varying concentrations of
the co-polymer, PEG 10,000 and the modifying agent, sodium
carbonate (Na2CO3). The blends were centrifuged at 3,500 rpm
for 15 minutes in order to remove any air bubbles. The aqueous
blends (30 g) were then slowly poured into moulds consisting of a
release liner with the siliconised surface facing upwards (Rayven,
Inc., Saint Paul, MN, USA) secured to a Perspex base plate with
stainless steel clamps. Once assembled, the internal dimensions
available for casting were 100 mm6100 mm. The aqueous blends
were spread evenly across the moulds and these were placed onto a
level surface. The cast blend was dried for 48 hours at room
temperature. After drying, the films were cured at 80uC for 24 h to
induce chemical crosslinking between the PMVE/MA and PEG
by ester formation [14,15]. Films were then removed from the
mould by simply peeling the release liner, with attached film, off
the base.
2.3. Swelling of hydrogel films in phosphate-buffered
saline (PBS)
For swelling studies, individual film portions (1 cm2) were
weighed at the zero time point in the dry state (m0) and then
placed into a volume of PBS (pH 7.4). The film portions were
removed at specific time points, surface fluid was removed
between pieces of filter paper and the mass of the swollen film
was recorded (mt). PBS was selected as the swelling medium, as it
was deemed to closely resemble/simulate skin interstitial fluid and
has been used as the swelling medium in other similar studies [14].
The percentage swelling of the film was determined using
Figure 1. Schematic representation of the concept of combin-
ing hydrogel-forming microneedles prepared from super
swelling polymers and lyophilised wafer-type drug reservoirs
for enhanced transdermal delivery of proteins and high dose
low potency drug substances.
doi:10.1371/journal.pone.0111547.g001
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Equation 1.
% Swelling ~
mt{mo
mo
 
x 100% ð1Þ
To examine the controlled swelling mechanism of the PEG-
crosslinked PMVE/MA hydrogels, a second order kinetic model
was used to process the experimental data, as outlined in
Equation 2, where A is the reciprocal of the initial swelling rate
of the hydrogel, ro, or 1/(ksSeq
2), where ks is the swelling rate
constant and B is the inverse of the degree of swelling at
equilibrium, Seq [16].
%EWC ~
me{md
md
x 100% ð2Þ
To analyse the kinetic model, t/S versus t graphs were plotted and
respective swelling rate parameters were determined [14]. The
dynamics of the water sorption process are usually investigated
either by monitoring the change in physical dimensions of the
swelling hydrogel or by knowing the amounts of water imbibed by
the hydrogel at various time points. In the current study, the latter
procedure was engaged. Analysis of the swelling kinetics of the
various films was carried out using Equation 3 [14]. The portion
of the water absorption curve with a fractional water uptake (Mt/
M‘) less than 0.60 was analyzed with Equation 4, where Mt is
the mass of water absorbed at time t, M‘ is the water uptake at
equilibrium. k is a gel characteristic constant, which depends on
the structural characteristics of the polymer and its interaction
with the solvent and n is the swelling exponent, describing the
mechanism of penetrant transport into the hydrogel. The
constants n and k may be calculated from the slopes and
intercepts of the plots of ln(Mt/M‘) versus ln t from the
experimental data. The value of n provides an indication of the
water transport mechanism. When n=0.5, the swelling process is
of Fickian nature and is diffusion controlled while the value of n
between 0.5 and 1 suggests non-Fickian diffusion or more
specifically anomalous diffusion. When n becomes exactly equal
to unity, then the diffusion is termed case II diffusion. In some
cases, the value for n has been found to exceed unity and this
represents super case II transport [17–19].
Figure 2. Schematic representation of casting and crosslinking of the super swelling hydrogel films (A), microneedle preparation
(B), Texture Analyser set-up for investigation of physical properties of microneedles (C) and Franz cell set-up for in vitro
transdermal drug release studies (D). Panel (E) shows a diagrammatic representation of the measurements recorded from the optical coherence
tomographic images of microneedle penetration into excised neonatal porcine skin in vitro, namely; (a) the distance between the lower microneedle
base plate and the stratum corneum, (b) the depth of microneedle penetration into the skin and (c) the width of the micropore created in the skin.
doi:10.1371/journal.pone.0111547.g002
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t=S~AzBt ð3Þ
Mt
M
~ktn ð4Þ
Hydrogel network structure characterization is a complex
procedure because of the many types of possible networks,
including, regular, irregular, loosely/highly cross-linked and
imperfect networks. As a result of these variations in the network
structure, only average values for the cross-linking density and
molecular weight (MW) between crosslinks are represented using
different experimental or theoretical methods [13,16–19]. In the
present study, the number average MW between cross-links, MC ,
was determined using equilibrium swelling theory, MC (Equi),
rather than glass transition temperature. The magnitude of MC
affected the mechanical and physical properties of crosslinked
polymers. The volume fraction of a polymer, w, in the swollen state
describes the amount of liquid that can be imbibed into a hydrogel
and is described as a ratio of the polymer volume to the swollen gel
volume (Equation 5 and 6).
MC (Equi)~
{dpVsw
1=3
½ In (1{w)zwzxw2 ð5Þ
w~ 1z
dp
ds
ma
mb
 
-
dp
ds
  -1
ð6Þ
Here, Vs is the molar volume of water (18 cm
3/mol), w is volume
fraction of polymer in the hydrogel, x is the Flory-Huggins
polymer-solvent interaction parameter; In the above Equation, ma
and mb are the mass of polymer before and after swelling and dr
and ds are the densities of polymer and solvent, respectively. The
density of the polymeric films was calculated using the following
formula; dr=w/SX, where; X is the average thickness of the film,
S is the cross-sectional area and w weight of the film. The polymer
water interaction parameter (x) reflects the thermodynamic
interaction in hydrogels, which in turn indicates the change of
interaction energy when polymer and solvent mix together. The x
parameters of hydrogels can be obtained experimentally via
Equation 7 [13,16–19].
x~
1
2
z
w
3
ð7Þ
Equation 7 neglects the Mc dependence of the x parameter, and
therefore, this equation indicates that the x values are always $
0.50. In the present study, crosslink density, Ve, was determined
using Equation 8. Ve represents the number of elastically effective
chains, totally induced in a perfect network, per unit volume.
Where, NA is Avagadro’s number (6.023610
23 mole21) [13,16–
19].
Ve~dpNA=Mc ð8Þ
2.4. Fabrication of hydrogel forming MN arrays
Formulations used to prepare MN were based upon the
preceding swelling studies. Aqueous blends containing 15% w/w
Gantrez AN-139 and 7.5% w/w PEG, 10,000 (control formula-
tion) [14] were utilized to fabricate MN arrays as previously
described [10,11]. The blend (500 mg) was poured into MN
moulds (361 (19619) needles perpendicular to the base and of
conical shape, 600 mm high with base width of 300 mm and 50 mm
interspacing on a 0.49 cm2 patch) and these were centrifuged at
3,500 rpm for 15 min and dried at room temperature for 48 h.
MN were crosslinked (esterification reaction) by heating at 80uC
for 24 hours [10,11,14] and the sidewalls formed by the moulding
process were removed using a heated blade (Figure 2B). MN
arrays were also prepared from a so-called ‘‘super swelling’’
hydrogel formulation containing 20% w/w Gantrez S-97, 7.5%
w/w PEG 10,000 and 3% w/w Na2CO3.
2.5. Mechanical characterisation of super swelling
microneedle arrays
MN were subjected to standard mechanical tests using a TA-
XT2 Texture Analyser (Stable Microsystems, Haslemere, UK) in
compression mode, as described previously [10,11,20]. Briefly,
MN arrays were visualised before testing using a light microscope
(GXMGE-5 digital microscope, Laboratory Analysis Ltd, Devon,
UK). MN arrays were then carefully placed on the flat stainless
steel baseplate of the Texture Analyser with the needles pointing
upwards. A flat-faced probe with a diameter of 11.0 mm was
lowered at a speed of 0.5 mm s21. Upon contact with the MN
array, the probe continued to travel at a speed of 0.5 mm s21 until
the required force had been exerted. Once the target force was
reached, the probe was moved upwards at a speed of 0.5 mm s21.
MN arrays were then viewed again under the light microscope.
2.6. Skin insertion studies
Neonatal porcine skin, a good model for human skin [21,22],
was obtained from stillborn piglets and immediately (,24 hours
after birth) excised, trimmed to a thickness of 700 mm using a
dermatome (Integra Life Sciences, Padgett Instruments, NJ, USA)
and frozen in liquid nitrogen vapour, as previously described
[10,11,20]. Skin was then stored in aluminium foil at 220uC for
no more than 7 days prior to use.
Skin was mounted on the baseplate of the Texture Analyser
using cyanoacrylate adhesive (Loctite Ltd, Dublin, Ireland) while
the MN were this time attached to the probe using double-sided
tape (3M, Carrickmines, Ireland). The probe then moved
downwards as described above until the required force had been
exerted. Once the target force was reached, the probe was moved
upwards at a speed of 0.5 mm s21. The number of MN in an array
that had penetrated the skin’s stratum corneum barrier was
counted following visualisation of the pores formed in skin using
methylene blue solution (1 mg/ml in PBS pH 7.4).
Optical coherence tomography (OCT), as described previously
[23] allowed measurement of the depth of MN insertion for each
application force, since the MN are transparent and accordingly
can be left in place during OCT studies to mimic their intended
use (EX1301 OCT microscope, Michelson Diagnostics, Kent,
UK). OCT was also used to visualise the in situ swelling of the MN
in real time skin at varying time intervals over a 3 h period. OCT
data files were exported to Image J (National Institutes of Health,
Bethesda, MD, USA) for measurement of insertion depth and false
colours were applied using Ability Photopaint (Ability Software
International, Horley, UK) for presentation purposes.
(5)
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2.7. Preparation and characterisation of lyophilised drug
reservoirs
A range of lyophilised wafer-type reservoirs loaded with the
model compounds ovalbumin (OVA) or ibuprofen sodium were
prepared containing varying concentrations of gelatin, mannitol
and, in some instances, sodium chloride (NaCl) and sucrose. In the
case of the ibuprofen sodium wafers, a variety of different gelatin
sources, all at loadings of 10% w/w, were tested in combination
with 3% w/w mannitol and 40% w/w ibuprofen sodium in
deionised water.
To prepare OVA-containing reservoirs, the protein (0.5% w/w)
was dissolved in distilled water, followed by the addition of gelatin,
mannitol, NaCl and sucrose. It was then mixed by speed mixer at
3,000 rpm for 60 s and sonicated at 37uC for 60 min. To prepare
the ibuprofen sodium-loaded reservoirs, the individual compo-
nents were mixed by speed mixer at 3,000 rpm for 60 s and
sonicated at 37uC for 60 min. The resulting OVA or ibuprofen-
sodium formulations were then cast (500 mg in the case of OVA-
loaded wafers and 250 mg in the case of ibuprofen sodium-loaded
wafers) into cylindrical moulds with one open end moulds
(diameter 15 mm, depth 5 mm), frozen at 280uC for a minimum
of 60 min and then lyophilised in the freeze-drier (Virtis
Advantage Bench top Freeze Drier System, SP Scientific,
Warminster PA, USA), according to the following regime: primary
drying for forty eight hours at a shelf temperature of 240uC,
secondary drying for ten hours at a shelf temperature of 20uC and
vacuum pressure of 50 mTorr.
Dried reservoirs were characterised using standard pharmaco-
poeial tests. Twenty reservoirs were selected randomly, weighed
individually and their average weight was calculated to determine
the weight uniformity. The percentage deviation of each reservoir
from the average weight was determined. The thickness of the
reservoirs was determined with a digital micrometer (Digital
Calliper, 0–150 mm, Jade Products Rugby Limited, Warwick-
shire, UK). Five reservoirs were used and average values were
calculated. Hardness was determined using a Copley Hardness
Tester (Copley Scientific, Nottingham, UK). Twenty reservoirs
were weighed (W0) and then placed in the Friabilitor (Copley
Scientific, Nottingham, UK). This was operated at 25 rpm for
4 min. The reservoirs were then weighed again (W). The %
friability was then calculated using Equation 9. OVA and
ibuprofen sodium contents were determined using the ELISA and
HPLC methods described below following dissolution of the
reservoirs in PBS pH 7.4.
% Friability~ W-W0=W0ð Þ  100% ð9Þ
2.8. In vitro release studies
The diffusion of ibuprofen sodium (MW 228.26 g/mol) and
OVA (MW 45,000 g/mol) from lyophilised active-loaded tablets
through hydrogel MN arrays and across neonatal porcine skin was
investigated in vitro using modified Franz diffusion cells (FDC-400
flat flange, 15 mm orifice diameter, mounted on an FDCD
diffusion drive console providing synchronous stirring at 600 rpm
and thermostated at 3761uC, Crown Glass Co. Inc., Sommerville,
NJ, USA), as described previously [4]. Briefly, neonatal porcine
skin was obtained from stillborn piglets and immediately (,
24 hours after birth) excised and trimmed to a thickness of 350 mm
using an electric dermatome. Skin was then stored in aluminium
foil at 220uC until required. Skin barrier function integrity was
confirmed in all cases using standard transepidermal water loss
measurements (VapoMeter, Delfin Technologies Ltd, Kuopio,
Finland), with any damaged skin immediately discarded. Neonatal
porcine skin samples were then shaved carefully so as not to
damage the skin (again confirmed by TEWL) and were then pre-
equilibrated in phosphate buffered saline (PBS), pH 7.4, for
15 minutes prior to the commencement of experimentation. A
circular specimen of the skin was secured to the donor
compartment of the diffusion cell using cynoacrylate glue (Loctite,
Dublin, Ireland) with the stratum corneum facing towards the
donor compartment. This was then placed on top of dental wax, to
give the skin support, and MN arrays inserted into the centre of
the skin section, using a spring activated applicator at a force of
11 N/array. The lyophilised active-loaded wafers (which had been
trimmed to size using a heated scalpel blade) were placed on the
top of the MN, with 20 ml water used to initiate adhesion. A
tubular stainless steel weight (diameter 11.0 mm, 3.5 g mass) was
then placed on top of this. The donor compartments were
mounted onto the receptor compartments and the Franz cell
donor compartments covered with laboratory film (Parafilm,
Pechiney Plastic Packaging, WI, USA) so as to avoid evaporation
of PBS over the course of experimentation. At predetermined time
intervals, a 200 ml sample was collected via the side arm of the
Franz cell and the receiver compartment immediately replenished
with an equivalent volume of release medium. OVA was
quantified again using ELISA, while ibuprofen sodium was
determined using HPLC.
2.9. In vivo evaluation of OVA and ibuprofen sodium
delivery through super swelling MN
Prior to experimentation, rats were acclimatised to laboratory
conditions for a 7 day period. Super swelling hydrogel MN arrays
were manually inserted into the skin at a site on the rats’ backs. An
aliquot of water (20 ml) was applied to the centre of the array and
the lyophilised reservoir (again trimmed to size) was placed on top
of this. A bespoke adhesive film (Scotchpak 9732, 3M, Carrick-
mines, Ireland, coated with a 1.0 mm layer of DuroTak 34-416A,
National Starch & Chemical Company, Bridgewater, NJ, USA)
was applied on top of, and around the edges of, the lyophilised
reservoirs to aid retention and provide occlusion. Following
application of this integrated system, blood samples were collected
at pre-defined time points over 24 h for analysis.
All animal experiments throughout this study were conducted
according to the policy of the federation of European Laboratory
Animal Science Associations and the European Convention for
the protection of vertebrate animals used for experimental and
other scientific purposes, with implementation of the principles of
the 3R’s (replacement, reduction, refinement). Ethical permission
specifically for the experiments described here was obtained from
the Queen’s University Animal Welfare and Ethics Review Board
and all researchers carrying out the work had Personal Licences
from the UK Home Office. To anaesthetise the animals, isoflurane
was used and carbon dioxide was used for euthanisation.
2.10. Extraction of plasma and drug
The following procedure was carried out in the case of
ibuprofen sodium-containing samples only. Control rat blood for
method development was obtained from healthy Sprague dawley
rats. Blood from culled rats was collected via heart puncture with a
heparinised syringe into ethylenediaminetetraacetic acid (EDTA)-
coated tubes. Plasma separation was performed by centrifuging the
blood at 5006g for 10 min in a refrigerated centrifuge (4uC). The
plasma was then aliquoted into microtubes and stored at 280uC
until required. In the case of standards used in assay development,
10 ml of ibuprofen-sodium working standard solutions were added
Hydrogel-Forming Microneedles with Lyophilised Wafers
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to 190 ml blank plasma. In the case of plasma samples from MN-
treated rats, the drug was extracted from the samples without the
addition of any endogenous drug. Samples were then vortex mixed
for 10 s in a poly(propylene) microtube and 500 ml each
acetonitrile (ACN) was added. The samples were vortex mixed
for 10 min and centrifuged at 14,0006 g for 10 min at 4uC. The
ACN extraction procedure was then repeated to ensure optimum
extraction of the drug. The sample mixture was placed in a
disposable glass culture tube and the extract dried under a stream
of nitrogen at 35uC for 50 min using a Zymark TurboVap LV
Evaporator Workstation (McKinley Scientific, Sparta, NJ, USA).
The residue was then reconstituted in 200 ml PBS (pH 7.4) and
collected into a microtube. This was then vortex mixed for 30 s
and centrifuged at 14,0006 g for 10 min at room temperature.
The supernatant was transferred into an auto sampler vial and
50 ml was injected onto the HPLC column and detection carried
out as outlined below. In the case of blood samples collected from
OVA- treated rats, plasma was separated from whole blood as
outlined and this was then quantified by ELISA experiments.
2.11. Pharmaceutical analysis of ibuprofen sodium
Ibuprofen sodium quantification in PBS (pH 7.4) and rat
plasma was performed using reverse-phase high performance
liquid chromatography (RP-HPLC) (Agilent 1200 Binary Pump,
Agilent 1200, Standard Autosampler, Agilent 1200 Variable
Wavelength Detector, Agilent Technologies UK Ltd., Stockport,
UK) with UV detection at 220 nm. Gradient separation was
achieved using an Agilent Eclipse XDB-C18 (5 mm pore size,
4.66150 mm) analytical column fitted with a guard cartridge of
matching chemistry. The mobile phase was 60%:40% metha-
nol:10 mM potassium phosphate (pH 4.6), with a flow rate of
1 ml min21, and a run time of 30 min per sample. The injection
volume was 50 ml. The chromatograms obtained were analysed
using Agilent ChemStation Software B.02.01. Least squares linear
regression analysis and correlation analysis were performed on the
calibration curves produced, enabling determination of the
equation of the line, its coefficient of determination and the
residual sum of squares (RSS). To determine the limit of detection
(LoD) and limit of quantification (LoQ), an approach based on the
standard deviation of the response and the slope of the
representative calibration curve was employed, as described in
the guidelines from the International Conference on Harmonisa-
tion (ICH) [24]. Ibuprofen sodium, either dissolved in PBS
(pH 7.4) (standards), or samples collected from the Franz cell
apparatus (unknowns), was quantified by injection of the sample,
following filter sterilisation through 0.2 mm filters, directly onto the
HPLC column. In the case of plasma samples, the drug was first
extracted from the plasma as described above and then the
resulting sample, which had been reconstituted in PBS (pH 7.4)
and filtered through a 0.2 mm filter, was injected onto the column.
The method parameters for detection of ibuprofen sodium in PBS
(pH 7.4) and plasma were identical.
2.12. Enzyme-linked immunosorbent assay (ELISA) for
detection of OVA
An OVA ELISA, developed as described previously [25], was
used to detect OVA in samples collected in both in vitro and in
vivo experiments. Briefly, monoclonal anti-chicken egg albumin
(ovalbumin) antibody produced in mouse (moAb) was diluted in
0.1 M bicarbonate buffer, pH 9.6 to the optimized concentration
of 2.5 mg/ml. An aliquot (50 ml) of anti-ovalbumin was dispensed
into the plate and incubated overnight at 4uC. The plate was filled
with washing buffer 0.05% v/v Tween-PBS and soaked for
30 seconds before discarded. This process was repeated 5 times.
Then, the plate was turned onto absorbance paper to remove any
remaining buffer. The plate was blocked with SuperBlock T20
buffer (150 ml/well) and incubated for 2 hours at room temper-
ature. For the calibration curve, OVA solutions were freshly
prepared at a concentration of 1 mg/ml in PBS produced
concentrations of 1 mg/ml to 10 ng/ml. A 50 ml of sample was
dispensed into wells, each sample was analysed in triplicate. The
plate was covered and incubated for 1 hour at room temperature.
The plate was washed and incubated with rabbit anti chicken
OVA polyclonal antibody conjugate with horse-radish peroxidase
(HRP) at the optimized concentration of 5 mg/ml in SuperBlock
T20 buffer for 1 hour at room temperature. After the plate was
washed, 50 ml of TMP was added to each well to detect antibody
binding and incubated for 15 min. Colour development was
ended using 50 ml/well of 4.0 M HCl and optical density was
measured at 450 nm using a microplate reader spectrophotometer
(EnSpire Multimode Plate Reader, PerkinElmer, Waltham, MA,
USA). In terms of the analysis of blood samples collected during in
vivo experiments, plasma was separated from whole blood as
outlined below and this plasma was then subjected to the ELISA
protocol outlined above.
2.13. Statistical analysis
Data was analysed, where appropriate, using the Student’s t-
test, one-way analysis of variance ANOVA, Mann-Whitney U-test
or Wilcoxon test. In each case, a p-value less than 0.05 was
considered to denote significance.
Results and Discussion
Microneedles (MN) prepared from hydrogel-forming materials
have a range of advantageous characteristics. Firstly, the delivered
dose is not limited by what can be loaded into, or onto the surface
of the needles themselves, since the drug is contained within an
attached patch-type drug reservoir. Secondly, controlled admin-
istration is possible for the first time with MN. Finally, since the
MN are removed intact, no polymer is deposited in skin, while the
inherent antimicrobial properties of the polymer composition used
and the fact that the needles are soft upon removal mean
transmission of infection from patient to patient is unlikely. To
date, we have employed such systems in the effective in vivo
delivery of potent biomolecules, such as insulin, and for sustained
administration of proteins and small molecules over hours or days
[10–12]. In order to take this technology to the next stage of
development, we must now move beyond simply controlling
transdermal permeation to demonstrate its utility in administration
of clinically-relevant doses of non-potent drugs and in rapid
delivery of large molecules with physicochemical properties similar
to vaccine antigens. Accordingly, in the present study, we used our
previous experience with hydrogels [13] to alter the MN
formulation to enhance its swelling capabilities and changed the
drug reservoir from a flexible polymeric patch to a lyophilised
wafer-like design. Using a hygroscopic reservoir is likely to have
two principal effects. Firstly, its high solid content and porous
nature will attract water from skin interstitial fluid by osmosis
through the hydrogel-forming MN, whose swelling rate will be
enhanced. Secondly, since such lyophilised systems are rapidly
soluble in water, the rate of drug dissolution and its subsequent
availability for diffusion will also be increased. These theories were
examined for the first time here using ibuprofen sodium and
ovalbumin as model compounds. Importantly, we also examined
MN arrays post removal, since it was possible that excessive
swelling would reduce mechanical integrity.
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Figure 3. Swelling curve for crosslinked hydrogel films prepared from aqueous blends containing 20% w/w PMVE/MA, 7.5% w/w
PEG and 3% Na2CO3 based on the increasing mass of the swelling array expressed as a percentage of the mass of a dry array
(Means ± SD, n=3) (A). Super swelling microneedle arrays prepared from aqueous blends containing 20% w/w PMVE/MA, 7.5% w/w PEG and 3%
Na2CO3 as (B) xerogel and (C) post-swelling for 3 hours in PBS pH 7.4. t/S versus t swelling curves of super swelling hydrogel prepared from aqueous
blends containing 20% w/w PMVE/MA, 7.5% w/w PEG and 3% Na2CO3 (Mean 6 SD, n= 3) (D). Digital microscope images of super swelling hydrogel-
forming MN (prepared from aqueous blends containing 20% w/w PMVE/MA, 7.5% PEG 10,000 and 3% Na2CO3) following the application of different
forces (0.05, 0.18, 0.36, 0.71 and 0.9 N/needle). These images are representative of the percentage reduction in the heights of needles on the MN
arrays observed following the application of the different forces (Means+SD, n= 3) (E). Digital images showing micropores in excised neonatal
porcine skin following application of different forces and subsequent staining with methylene blue solution post microneedle removal (F).
Attenuated total reflectance (ATR)-Fourier transform infrared (FTIR) spectra of dry hydrogels prepared from aqueous blends containing: 20% w/w
Gantrez S-97, 7.5% w/w PEG 10.000 non crosslinked (a) and crosslinked (b) materials; Na2CO3 (c) and 20% w/w Gantrez S-97, 7.5% w/w PEG 10.000
and 3% w/w Na2CO3 non crosslinked (d) and crosslinked (e) materials. The left panel shows a closer view of the carbonyl region for the same
materials. A FTIR Accutrac FT/IR-4100 Series (Jasco, Essex, UK) equipped with MIRacle diamond ATR was used at room temperature. Samples were
scanned and recorded in the region of 4000–400 cm21 at a resolution of 4.0 cm21. The obtained spectra were an average of 64 scans. A standard
smoothing process was applied to all the spectra using the equipment software (G).
doi:10.1371/journal.pone.0111547.g003
Table 1. Aqueous blends used to prepare hydrogel formulations tested in the current study and the equilibrium swelling of the
formed hydrogels (Means 6 SD, n = 3).
Formulation no.
Ingredients (pH value of Gantrez gel prior to addition of other
ingredients and making up to volume with deionised water) Percentage swelling at equilibrium
Control formulation 15% w/w Gantrez AN-139 (pH 2) 7.5% w/w PEG 10,000 10716106
1 15% w/w Gantrez S-97, (pH 2) 7.5% w/w PEG 10,000 918613
2 20% w/w Gantrez S-97, (pH 2) 7.5% w/w PEG 10,000, 3% w/w Na2CO3 17086125
3 15% w/w Gantrez AN-139, (adjusted to pH 4) 7.5% w/w PEG 10,000, 3% w/w Na2CO3 Dissolved
4 16% w/w Gantrez AN-139, (adjusted to pH 4) 6% w/w PEG 10,000, 3% w/w Na2CO3 Dissolved
doi:10.1371/journal.pone.0111547.t001
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3.1. Swelling studies
The results outlined in Figure 3A display the percentage
swelling in PBS pH 7.4 of super swelling hydrogel films cast from
aqueous blends of 20% w/w Gantrez S-97, 7.5% w/w PEG
10,000 and 3% w/w Na2CO3. The hydrogel formulation
incorporating Na2CO3 as a modifying agent showed greater
initial swelling and reached equilibrium more quickly than the
control formula (15% Gantrez AN-139, 7.5% PEG). For example,
after 1 hour, the percentage swelling of super swelling hydrogels
(20% w/w Gantrez S-97, 7.5% w/w PEG and 3% w/w Na2CO3)
was 1119%, compared to only 250% for the control formulation.
Hydrogels prepared from aqueous blends containing 3% w/w
Figure 4. False colour 2D still images of super swelling MN arrays immediately following insertion into excised neonatal porcine
skin at application forces of 4, 7, 11 or 16 N/array or using manual application. (Scale bar represents 300 mm in each case) (A). The effect of
application force (N/array) upon the resultant penetration depth of super swelling MN arrays in neonatal porcine skin in vitro, expressed as a p
[percentage of MN height (Means+S.D., n = 10)]. The penetration parameters of the MN arrays were quantified using optical coherence tomography
(B). False colour images of the in vitro swelling profile of MN arrays in excised neonatal porcine skin recorded over a 3 h period, as assessed by optical
coherence tomography (Scale bar represents 300 mm in each case) (C). OCT visualisation of the micropores residing within the skin immediately
following MN array insertion (0 min) and following 60 min in skin (Scale bar represents 300 mm. in each case) (D).
doi:10.1371/journal.pone.0111547.g004
Table 2. The effect of force of application upon the resultant penetration characteristics of MN arrays cast from 20% w/w Gantrez
S-97, 7.5% w/w PEG 10,000 and 3% w/w Na2CO3, in the geometry 19619 with height 600 mm, width 300 mm and interspacing at
base 50 mm into neonatal porcine skin, (Means 6 SD, n = 10).
Force (N/array) MN penetration depth (mm) Pore width (mm) Base plate/Stratum corneum distance (mm)
4 201631 209610 398631
7 322635 214617 277635
11 430620 21968 169620
16 57168 228612 2968
Manual 465628 21167 134628
doi:10.1371/journal.pone.0111547.t002
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Na2CO3 showed a significant (p,0.05) increase in percentage
swelling. The percentage swelling at equilibrium was 1071% and
1708% for the control and super swelling formulations, respec-
tively (Table 1). Figure 3 also illustrates the morphology of the
MN array as a xerogel (B) and post-swelling in PBS (C).
Figure 3D is representative of the liner regression plots derived
from swelling curves using Equation 3.
Using attenuated total reflectance (ATR)-Fourier transform
infrared (FTIR) spectroscopy, the mechanism of action of the
modifying agent was confirmed to be due to sodium salt formation
on free acid groups on the copolymer, thus reducing ester-based
crosslinking (Figure 3G). The main difference that can be seen in
the spectra of the crosslinked films in contrast with the non
crosslinked ones, is the presence of a new band between 1800 and
1750 cm21. This band can be attributed to the new ester bonds
formed between the Gantrez S-97 acid groups and the hydroxyl
groups of the PEG molecules. In addition a new band between
1500 and 1600 cm21 can be observed for super-swelling hydrogels
that is not present in the other hydrogels. This band is
characteristic for the salts of carboxyilic acids [26].
To examine the controlling mechanism of swelling of the super
swelling hydrogel materials prepared from aqueous blends of 20%
w/w Gantrez S-97, 7.5% w/w PEG and 3% w/w Na2CO3, the
second order kinetic model (Equation 4) was used to process the
experimental data. To analyse the kinetic model, t/S versus t
graphs were plotted and respective swelling rate parameters were
determined. Figure 3D shows representative linear regression
plots of the swelling curves derived from Equation 4. The
diffusional exponent, n, was determined to be 0.76, indicating an
anomalous mechanism of water uptake. In addition, the diffusion
coefficient (Di) was 2.47610
26 cm2 min21. The volume fraction
of polymer, w, determined using Equation 6 was 0.045, the
number average molecular weight between crosslinks, Mc,
determined using Equation 5, was 6,793,627 g/mol. The
crosslink density, Ve, determined using Equation 8 was
1.0861019. Due to dissolution of other candidates, the formulation
which was selected for continued investigation was that containing
20% w/w Gantrez S-97, 7.5% w/w PEG and 3% w/w Na2CO3.
3.2. Mechanical testing
MN arrays formulated using the super swelling formulation
(20% w/w Gantrez S-97, 7.5% w/w PEG and 3% w/w Na2CO3)
and in the geometry, 19619 (height = 600 mm, width= 300 mm,
interspacing = 50 mm) were used to investigate the effects of
compression tests on the heights of individual needles on the MN
array. The digital microscope images presented in Figure 3E are
illustrative of the effects, on individual needles of the MN array, of
the fracture forces applied by axial load. It is important to note
that regardless of the force applied, none of the needles on the MN
array broke or shattered upon application into the skin, rather
bending. Figure 3E also shows the percentage reduction in the
height of individual needles on the MN array upon application of
increasing fracture forces. The reduction in MN height increased
progressively with increases in the force applied. These MN
deformed when applied to a stainless steel plate, but were not
brittle, which is important from a patient safety point of view. This
is especially true considering the relatively high forces applied here
(.300 N was the maximal force applied over the 361 MN) and the
much softer nature of skin.
Skin penetration of super swelling MN arrays was investigated
using dermatomed neonatal porcine skin (approximately 350–
450 mm thicknesses) and the percentage of holes (micro-conduits)
created by the MN arrays was determined after staining of the skin
Table 3. In vitro swelling of MN arrays (19619 MN, 600 mm height, 300 mm width at base, 50 mm interspacing at base) upon
insertion into neonatal porcine skin, (Means 6 SD, n = 15).
Time (min) MN depth in skin (mm)
0 465.25628.25
30 578.08622.74
60 609.50635.13
180 697.27641.63
doi:10.1371/journal.pone.0111547.t003
Table 4. Physical properties of lyophilised drug reservoirs.
Parameter Means ± S.D.
Ovalbumin
Weight (g) 0.3260.01
Hardness (N) 119.765.0
Thickness (mm) 4.1260.3
Friability 0.47% mass loss
Ibuprofen sodium
Weight (g) 0.2660.02
Hardness (N) 17863
Thickness (mm) 4.9660.6
Friability 0% mass loss
doi:10.1371/journal.pone.0111547.t004
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with methylene blue solution. Regardless of force applied,.85%
of the MN in each array penetrated the stratum corneum, as
evidenced by staining of the formed aqueous microconduits by the
hydrophilic marker compound. However, with increasing applied
forces, the penetration efficiency of the MN also increased
(Figure 3F). In the case of the 0.9 N/needle applied force, the
microconduits created could be traced onto the surface of the
laboratory film (Parafilm) placed beneath the skin. This indicated
that, at this highest insertion force, which equates to 324.9 N/
array as there are 361 needles in each array, the depth of
penetration of the needles into the skin was at its greatest. In order
to accurately measure miroconduit depth, optical coherence
tomography was utilised. The penetration characteristics of MN
arrays inserted into neonatal porcine skin using an applicator set to
defined forces of 4, 7, 11 or 16 N/array are presented in Table 2
and Figure 4B. Manual force (defined as ‘‘gentle finger
pressure’’) was also used to insert the MN arrays and the
penetration characteristics are very similar to those quoted when a
force of 11 N/array was employed. Increasing force increased
penetration depth and decreased distance between the lower MN
baseplate and the stratum corneum, but microconduit width was
largely unaffected.
3.3. In skin swelling
The swelling of the MN arrays upon application into skin was
then investigated in vitro over 3 hours and in real time. Individual
needles on the arrays exhibited an increase in height of
approximately 40% by the end of the three-hour testing period
(Figure 4C and Table 3). The microconduits residing within the
skin immediately and 60 min post-MN array application were
visualised (Figure 4D). Importantly, these images confirm that
skin under occlusion swells and relaxes with the MN, meaning
their increase in volume does not result in the extravasation of the
swollen MN from the skin.
3.4. Lyophilised drug reservoirs
Different OVA-loaded and ibuprofen sodium-loaded formula-
tions were prepared and lyophilised. An OVA-loaded formulation
containing 10% w/w gelatin (Sigma-Aldrich, Dorset, UK), 40%
w/w mannitol (Sigma-Aldrich, Dorset, UK), 10% w/w NaCl, 1%
w/w sucrose and 0.5% w/w OVA was determined to be the most
suitable, in terms of morphology, strength and dissolution profile
of the formed wafers and, hence, was chosen for further
characterisation studies. In terms of the ibuprofen sodium, those
wafers which were prepared from blends containing 10% w/w
gelatin (Cryogel SG3, PB Gelatins, Pontypridd, UK), 3% w/w
mannitol (Pearlitol 50C-Mannitol, Roquette, Lestrem, France) and
40% w/w ibuprofen sodium (Sigma-Aldrich, Dorset, UK) were
chosen for subsequent investigation, as they were the most
homogeneous. There was no loss of active in either case, with
recoveries of 100% for ibuprofen sodium and 98618% for OVA.
In addition, the wafers all complied with pharmacopoeial
standards [27] for hardness, weight variation, thickness and
friability (Table 4).
3.5. In vitro drug release studies
Ibuprofen sodium exhibited an almost typical first order release
profile across excised neonatal porcine skin in vitro (Figure 5A),
with approximately 44 mg delivered in 24 h (range from 9
replicates: 35.2–68.9 mg over 24 h). As the ibuprofen sodium-
loaded reservoirs were known to contain a mean loading of
124 mg approximately 37% of this was delivered in 24 h. OVA
exhibited a tri-phasic release profile (Figure 5D), possibly due to
the very different composition and morphology of the lyophilised
Figure 5. The in vitro cumulative permeation profile of ibuprofen sodium across dermatomed 350 mm neonatal porcine skin when
delivered using in-dwelling super swelling MN arrays combined with lyophilised drug reservoirs (Means ± S.D., n =9) (A). Digital
images of the ibuprofen sodium-loaded lyophilised wafers used in in vitro and in vivo experiments and prepared from aqueous blends containing
10% w/w gelatin, 3% w/w mannitol and 40% w/w ibuprofen sodium (B, C). The in vitro cumulative permeation profile of OVA across dermatomed
350 mm neonatal porcine skin when delivered using in-dwelling super swelling MN arrays combined with lyophilised drug reservoirs (Means 6 S.D.,
n = 5) (D). Digital images (E, F)of the OVA-loaded lyophilised wafers used in in vitro and in vivo experiments and prepared from aqueous blends
containing 10% w/w gelatin, 40% w/w mannitol, 10% w/w NaCl, 1% w/w sucrose and 0.5% w/w OVA. These active-loaded tablets exhibited high
porosities as exemplified in (G).
doi:10.1371/journal.pone.0111547.g005
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wafers (Figure 5F) and the much greater molecular weight and
more complex molecular structure, as compared to ibuprofen
sodium. The average total OVA content of the lyophilised wafers
was 2.560.15 mg and it was found that the super swelling MN
arrays delivered approximately 1.24 mg OVA over the 24 h
experimental period (range from 5 replicates: 1.09–1.36 mg over
24 h). This equates to transdermal delivery of approximately 49%
of the OVA loaded into the wafers on average. This is interesting
to note, since such effective in vitro transdermal delivery has not
been seen previously for either high dose low potency molecules or
proteins. However, it is unsurprising, given the high molecular
weight between crosslinks of the super swelling hydrogel calculated
at equilibrium (6,793,627 g/mol) compared to the molecular
weights of ibuprofen sodium (229.29 g/mol) and even ovalbumin
(44,300 g/mol). Drug permeation is thus likely to be affected more
by the dissolution rate of the lyophilised wafers than the hydrogel
material, assuming in-skin swelling is complete.
3.6. In vivo experiments
In the case of experiments carried out using OVA-loaded
reservoirs, two super swelling MN arrays and active-loaded wafers
were applied to the backs of the animals (Figure 6A). In contrast,
four MN arrays and their respective ibuprofen sodium-loaded
reservoirs were applied to the backs of the animals in parallel drug
delivery experiments. Plasma profiles in the case of both model
compounds differed from the patterns of drug permeation profiles
seen in vitro. This is unsurprising, given that the two experiments
are distinct from one another, since the in vitro experiments do not
have biodistribution, metabolism or excretion components as we
have in vivo.
For ibuprofen sodium (Figure 6B), the integrated MN array
delivery system produced a progressive increase in plasma
concentrations over 6 h, with a maximal concentration of
approximately 179 mg/ml achieved in this time. The plasma
concentration had fallen to 71+6.7 mg/ml by 24 h. Therapeutic
plasma levels of ibuprofen in humans range between 10 and
15 mg/ml [28] and these levels were achieved within the first hour
of MN application. Based on this knowledge and the in vivo
results, we can approximate the patch size necessary for use in
human volunteer studies. An average human male weighs
approximately 60 kg [29], which is 286 times greater than the
weight of a 210 g rat (the average weight of rat used in these
experiments). The peak plasma ibuprofen sodium concentration
achieved in the rats at 6 h (179619 mg/ml) is approximately 18
times greater than the human therapeutic blood levels [28] and
this was achieved with MN arrays of total approximate area of
2 cm2 (460.5 cm2). By this rationale, a MN patch design of no
greater than 32 cm2 could potentially deliver therapeutically-
relevant doses of ibuprofen sodium in healthy volunteer studies.
Typical commercialised transdermal patches can be as large as 30
Figure 6. Schematic representation of application and retention strategies for rat experiments designed to evaluate in vivo
performance of super swelling microneedle arrays (A). The in vivo plasma profiles of ibuprofen sodium (B) (Means 6 S.D., n = 4) and OVA (C)
(Means 6 S.D., n = 3) following transdermal delivery using super swelling microneedle arrays with lyophilised drug reservoirs. Typical morphology of
super swelling microneedles upon removal from rat skin in vivo after 24 hours insertion indicating that, despite extensive swelling, the microneedles
are removed intact (D, E).
doi:10.1371/journal.pone.0111547.g006
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or 40 cm2 (Novartis make Nicotinell nicotine patches of 30 cm2
[30]; Janssen make Duragesic CII (fentanyl) patches of 32 and
42 cm2 [31]). Accordingly, it is very reasonable to suggest that a
MN product could be successfully developed based on the
technology and data presented here. Indeed, we have previously
shown that scaling up MN patch size is a relatively straightforward
process [8,10].
OVA levels peaked in plasma after only 1 hour (Figure 6C) at
42.36617.01 ng/ml. This represents a significant finding, since
macromolecules are normally absorbed quite slowly when
administered intradermally [4,5] OVA plasma levels then
remained almost constant up to 6 h, dropping somewhat at
24 h, when 23.6164.84 ng/ml was detected.
Importantly, the super swelling hydrogel MN arrays remained
intact over the 24 h application period in all cases, thus allowing
their removal as an intact unit at the end of the experiment
(Figure 6D, E). As can be appreciated, the MN array extensively
absorbed interstitial fluid to form a swollen hydrogel matrix, thus
enabling delivery of OVA and ibuprofen sodium across the skin
and into the systemic circulation. However, the system was
sufficiently robust when swollen to ensure that the MN were
removed intact.
Conclusions
The work presented here shows, for the first time, that
exploitation of so-called ‘‘super swelling’’ hydrogel materials in
microneedle-enhanced transdermal drug delivery is a highly
promising approach to increasing the range of drugs that can be
delivered transdermally. Using such systems in combination with
lyophilised wafer-type drug reservoirs facilitated delivery of doses
of ibuprofen sodium that could be extrapolated to a useful and
usable product for human treatment. Rapid protein delivery using
ovalbumin as the model indicated that this technology may also
find use in macromolecular drug delivery and vaccine adminis-
tration. The value to industry is likely to be considerable, since this
technology is distinctly different from conventional microneedle
systems, which are presently only suitable for bolus delivery of very
potent drugs and vaccines. Accordingly, we are currently
progressing towards clinical evaluations with a range of candidate
molecules.
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